Krauss J, van der Linden M, Grebe T, Hakenbeck R
Max-Planck Institut für Molekulare Genetik, Berlin, Germany.
Microb Drug Resist. 1996 Summer;2(2):183-6. doi: 10.1089/mdr.1996.2.183.
Different penicillin-binding proteins PBPs are affected in cefotaxime-resistant laboratory mutants compared to piperacillin-resistant mutants. PBP2x acts as the primary PBP target in cefotaxime-resistant mutants, whereas PBP2b is the primary target in piperacillin-resistant mutants. Depending on the mutations in PBP2x, it functions as a resistance determinant for cefotaxime only, or for penicillins as well. Mutations in PBP2x of laboratory mutants are found exclusively in the penicillin-binding domain that contains three homology boxes common to all penicillin-interacting enzymes. Most mutations relevant for resistance occur close to the SXN or the KT/SG box, or at the C-terminal end of the penicillin-binding domain, similar to mutations described in PBP2b of laboratory mutants. Amino acid alterations occur at similar sites also in PBP2x of beta-lactam-resistant clinical isolates and most of these proteins also contain changes in the SXXK box with the active site serine, suggesting that these alterations may be critical for resistance development in clinical isolates.
与哌拉西林耐药突变体相比,不同的青霉素结合蛋白(PBPs)在头孢噻肟耐药实验室突变体中受到影响。在头孢噻肟耐药突变体中,PBP2x作为主要的PBP靶点,而在哌拉西林耐药突变体中,PBP2b是主要靶点。根据PBP2x中的突变情况,它仅作为头孢噻肟的耐药决定因素,或同时作为青霉素的耐药决定因素。实验室突变体的PBP2x突变仅出现在青霉素结合域,该区域包含所有与青霉素相互作用酶共有的三个同源框。与耐药相关的大多数突变发生在靠近SXN或KT/SG框的位置,或在青霉素结合域的C末端,这与实验室突变体的PBP2b中描述的突变类似。β-内酰胺耐药临床分离株的PBP2x中也在相似位点发生氨基酸改变,并且这些蛋白中的大多数在含有活性位点丝氨酸的SXXK框中也有变化,这表明这些改变可能对临床分离株的耐药发展至关重要。